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1  | BACKGROUND
Current available maintenance pharmacotherapy for bipolar disor‐
der (BD) leaves ample room for improvement. Up to 50% of patients 
with BD do not respond adequately to available treatments and still 
suffer from manic and/or depressive episodes. Although a number 
of pharmaceutical companies have invested in novel medications, 
none of the recently developed compounds has shown efficacy for 
recurrence prevention.
Given that BD is associated with dysregulations of the immune 
system, there is increasing interest in the therapeutic potential of 
immune‐modulating medications. Although aspirin (acetylsalicylic 
acid) has been investigated to treat depressive symptoms,1 low‐dose 
(typically	≤150	mg/day)	aspirin	may	be	a	particularly	promising	can‐
didate for recurrence prevention: it is well tolerated, even with long‐
term use, well absorbed, passes the blood‐brain barrier, and likely 
exerts anti‐inflammatory effects in both the brain and the periphery.
In this perspective article, we will give an overview of the neu‐
ropharmacodynamics of (low‐dose) aspirin, reflect on the published 
clinical studies and argue that aspirin is a promising, yet understud‐
ied option for recurrence prevention.
2  | PATHOPHYSIOLOGIC AL MECHANISMS
Aspirin can exert its effect on the neuroimmune system in BD via 
two pathways: modification of the cyclooxygenase enzymes (COX 
enzymes) and by stimulation of myelinization. Aspirin is unique 
among the NSAIDs in that it covalently modifies COX‐1 and COX‐2 
where it has differential effects.2 Aspirin treatment of COX‐1 ir‐
reversibly inhibits the cyclooxygenase activity of the enzyme and 
subsequently the production of prostaglandin G2 (PGG2), block‐
ing the conversion of arachidonic acid (AA) to prostaglandins and 
thromboxane A2. In the brain, COX‐1 is predominantly expressed 
by microglia, known to be activated in BD. Preclinical evidence 
suggests that inhibition of COX‐1 is neuroprotective after intrac‐
erebroventricular administration of lipopolysaccharide (LPS).2 In 
contrast to full inhibition of COX‐2 by selective COX‐2 inhibitors, 
which is thought to have detrimental effects by increasing leuko‐
cyte recruitment into the brain and exacerbating tissue damage,2 
aspirin acetylation of COX‐2 results in a shift in reaction specificity, 
converting enzyme activity from a cyclooxygenase to a lipoxyge‐
nase. Lipoxygenase activity results in the generation of anti‐inflam‐
matory mediators such as lipoxin A4 and 15‐epi‐lipoxin A4, as well 
as docosahexaenoic acid (DHA) to 17‐(R)‐OH‐DHA. The increase 
of these anti‐inflammatory lipoxygenase metabolites is dose de‐
pendent, being increased in low‐dose aspirin treated humans in a 
randomized trial by Chiang et al. Interestingly, aspirin shares these 
effects with lithium synergistically, which was found to reduce rat 
brain COX‐2 activity and prostaglandin E2 (PGE2) concentration, 
while increasing brain concentrations of DHA‐derived anti‐inflam‐
matory metabolites.
Lithium and low‐dose aspirin in BD may have an additional syn‐
ergistic mode of action, involving the myelination of white matter 
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tracts.3 Results from anatomical magnetic resonance imaging (MRI) 
and more recent whole‐brain diffusion tensor imaging (DTI) studies 
suggest widespread white matter abnormalities in BD, associated 
with mood episodes and cognitive functioning. A DTI study that we 
performed demonstrated myelination aberrations in lithium‐using 
patients with BD compared to non‐lithium‐using patients in large 
white matter fibers, comparable to observations made in another 
DTI study by Benedetti et al. Based on these observations, it has 
been suggested that lithium may have a counteracting effect on 
white matter microstructural disturbances, possibly being one of 
its therapeutic mechanisms, via a known inhibition of glycogen syn‐
thase kinase 3 beta (GSK‐3β). Interestingly, low‐dose aspirin was also 
found to have a stimulating effect on myelin‐forming oligodendro‐
cytes in mice,3 potentially enhancing the effect of lithium via this 
route. In oncological research, aspirin is known to have an inhibitory 
effect on GSK‐3β as well.
3  | CLINIC ALLY UNDERSTUDIED
Aspirin has been investigated in only three published clinical studies 
on treatment of mood and medication side effects in BD.
Savitz et al. tested the efficacy of aspirin and minocycline as aug‐
mentation therapy for bipolar depression.1 Ninety‐nine depressed 
outpatients with BD were enrolled in a 6 week, double‐blind, pla‐
cebo‐controlled trial, and randomized to one of four groups with 
equal allocation probability: active minocycline (100 mg b.i.d.) + ac‐
tive aspirin (81 mg b.i.d.) (M + A); active minocycline + placebo 
aspirin (M + P); placebo‐minocycline + active aspirin (P + A); and 
placebo‐minocycline + placebo aspirin (P + P). When all four arms 
were included in the analysis, there was a main effect of aspirin on 
depressive symptoms that was driven by both the M + A and the 
P + A groups (p(two‐tailed) = 0.019, odds ratio = 3.7, number needed 
to treat = 4.0).
Stolk et al performed a pharmacoepidemiological study related 
to BD4 in which medication histories on subjects who had been pre‐
scribed lithium were collected using health care registry data. After 
stratification of drug classes that inhibit phospholipase A2 (PLA2) 
and/or COX enzymes, and duration of use, incidence density (ID) of 
medication events (dose increase or substance change) was com‐
pared as a proxy for clinical worsening. Low‐dose aspirin produced 
a statistically significant duration‐independent reduction in the rela‐
tive risk of clinical deterioration in subjects on lithium (ID ratio 0.82), 
whereas other NSAIDs and glucocorticoids did not.
Saroukhani et al assessed the effect of 240 mg aspirin on lithium‐
related sexual dysfunction in 32 men with stable bipolar affective 
disorder in a 6 week randomized, double‐blind, placebo‐controlled 
study.5 At the end of the study, patients in the aspirin group showed 
significantly greater improvement in total sexual function (63.9% im‐
provement from baseline) and erectile function domain (85.4% im‐
provement from baseline) scores than the placebo group (14.4% and 
19.7% improvement, respectively). The mood symptoms remained 
stable over the course of the study.
There were no severe adverse events related to aspirin in any of 
these studies. Of particular importance in BD, low‐dose aspirin does 
not increase serum lithium, contrary to other NSAIDs.
4  | DISCUSSION
The study by Savitz et al points toward an ameliorating effect of 
aspirin on depressive symptoms in BD. Since the pathophysiologi‐
cal action of immune modulators primarily focuses on improving the 
stability of the underlying dysregulated immune and glial cells, they 
may be even more effective in preventing recurrences.
It is interesting that this hypothetical recurrence‐preventing 
mode of action of low‐dose aspirin is supported by the pharmaco‐
epidemiological study by Stolk et al. In this study, low‐dose aspirin 
was found to have a statistically significant duration‐independent 
reduction in the relative risk of clinical deterioration, when com‐
pared to subjects not using aspirin.4 Indeed, studies that investi‐
gated cytokines, gene‐expression, T‐cell populations, and CRP 
across mood states, including those from our group, have shown 
the immune system to be more severely dysregulated during mood 
episodes. Nevertheless, clinical trials to improve mood stability and 
reduce the recurrence rate by administration of aspirin to stabilize 
the immune system in (a more immune dysregulated subgroup of) 
patients with BD have never been performed. In conclusion, the 
high burden of illness in combination with the limited available 
treatment options make the clinical investigation of a recurrence‐
preventing mode of action of low‐dose aspirin in BD an important 
endeavor. Since aspirin's patent has passed historically long ago, it 
is unlikely pharmaceutical companies will investigate this possible 
new indication. However, when proven to be efficacious in patients 
with BD, this would be of great clinical relevance since aspirin is 
well tolerated, has other beneficial health effects, is affordable, and 
therefore would have a strong favorable cost/benefit ratio, empha‐
sizing the importance of public funding for such trials.
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